Literature DB >> 22304708

Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.

J Pavlícek1, J Ptácek, C Barinka.   

Abstract

Recent years witnessed rapid expansion of our knowledge about structural features of human glutamate carboxypeptidase II (GCPII). There are over thirty X-ray structures of human GCPII (and of its close ortholog GCPIII) publicly available at present. They include structures of ligand-free wild-type enzymes, complexes of wild-type GCPII/GCPIII with structurally diversified inhibitors as well as complexes of the GCPII(E424A) inactive mutant with several substrates. Combined structural data were instrumental for elucidating the catalytic mechanism of the enzyme. Furthermore the detailed knowledge of the GCPII architecture and protein-inhibitor interactions offers mechanistic insight into structure-activity relationship studies and can be exploited for the rational design of novel GCPII-specific compounds. This review presents a summary of structural information that has been gleaned since 2005, when the first GCPII structures were solved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304708     DOI: 10.2174/092986712799462667

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  19 in total

1.  Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.

Authors:  Michal Navrátil; Jakub Ptáček; Pavel Šácha; Jana Starková; Jacek Lubkowski; Cyril Bařinka; Jan Konvalinka
Journal:  FEBS J       Date:  2014-06-17       Impact factor: 5.542

2.  A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.

Authors:  Tanushree Ganguly; Shorouk Dannoon; Mark R Hopkins; Stephanie Murphy; Hendry Cahaya; Joseph E Blecha; Salma Jivan; Christopher R Drake; Cyril Barinka; Ella F Jones; Henry F VanBrocklin; Clifford E Berkman
Journal:  Nucl Med Biol       Date:  2015-06-09       Impact factor: 2.408

3.  Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase II.

Authors:  Glenda Alquicer; David Sedlák; Youngjoo Byun; Jirí Pavlícek; Marigo Stathis; Camilo Rojas; Barbara Slusher; Martin G Pomper; Petr Bartunek; Cyril Barinka
Journal:  J Biomol Screen       Date:  2012-06-29

4.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

5.  Structural and biochemical characterization of a novel aminopeptidase from human intestine.

Authors:  Jan Tykvart; Cyril Bařinka; Michal Svoboda; Václav Navrátil; Radko Souček; Martin Hubálek; Martin Hradilek; Pavel Šácha; Jacek Lubkowski; Jan Konvalinka
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

Review 6.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

7.  Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.

Authors:  Jiri Pavlicek; Jakub Ptacek; Jiri Cerny; Youngjoo Byun; Lubica Skultetyova; Martin G Pomper; Jacek Lubkowski; Cyril Barinka
Journal:  Bioorg Med Chem Lett       Date:  2014-03-28       Impact factor: 2.823

8.  Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.

Authors:  Shorouk Dannoon; Tanushree Ganguly; Hendry Cahaya; Jonathan J Geruntho; Matthew S Galliher; Sophia K Beyer; Cindy J Choy; Mark R Hopkins; Melanie Regan; Joseph E Blecha; Lubica Skultetyova; Christopher R Drake; Salma Jivan; Cyril Barinka; Ella F Jones; Clifford E Berkman; Henry F VanBrocklin
Journal:  J Med Chem       Date:  2016-06-13       Impact factor: 7.446

9.  Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.

Authors:  Sridhar Nimmagadda; Mrudula Pullambhatla; Ying Chen; Princy Parsana; Ala Lisok; Samit Chatterjee; Ronnie Mease; Steven P Rowe; Shawn Lupold; Kenneth J Pienta; Martin G Pomper
Journal:  J Nucl Med       Date:  2017-10-12       Impact factor: 10.057

10.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.

Authors:  Zora Novakova; Jiri Cerny; Cindy J Choy; Jessie R Nedrow; Joeseph K Choi; Jacek Lubkowski; Clifford E Berkman; Cyril Barinka
Journal:  FEBS J       Date:  2015-11-05       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.